CCNB2: Cyclin B2 – A Key Regulator of the G2/M Cell Cycle Checkpoint
Comprehensive genomic and proteomic overview of CCNB2, including its role in cell cycle control, expression patterns, and implications in cancer and other diseases.
Gene Information Card
| Symbol | CCNB2 |
|---|---|
| Full Name | Cyclin B2 |
| Gene Type | Protein coding |
| Chromosomal Location | 15q22.2 |
| NCBI Gene ID | 9133 ncbi.nlm.nih.gov/gene/9133 |
| Ensembl ID | ENSG00000157456 |
| UniProt ID | O95067 |
| OMIM ID | 602755 |
| HGNC ID | 1590 |
| Aliases | Cyclin B2, G2/mitotic-specific cyclin B2 |
Description
CCNB2 encodes cyclin B2, a member of the cyclin family that regulates the G2/M transition of the cell cycle. Cyclin B2 binds to and activates CDK1 (cyclin-dependent kinase 1), forming the maturation-promoting factor (MPF) essential for mitosis. Unlike cyclin B1, cyclin B2 is predominantly localized to the Golgi apparatus and is involved in Golgi fragmentation during mitosis. CCNB2 expression is cell cycle-dependent, peaking during G2/M phase. Dysregulation of CCNB2 is implicated in various cancers, where overexpression correlates with poor prognosis and tumor progression.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Overexpression of CCNB2 promotes G2/M transition and cell proliferation; associated with poor prognosis | PMID: 25691885 |
| Colorectal cancer | Elevated CCNB2 expression linked to tumor growth and metastasis via CDK1 activation | PMID: 28411373 |
| Lung adenocarcinoma | CCNB2 upregulation correlates with advanced stage and reduced survival | PMID: 31591464 |
| Gastric cancer | High CCNB2 expression associated with increased proliferation and chemoresistance | PMID: 29348623 |
| Hepatocellular carcinoma | CCNB2 overexpression drives cell cycle progression and is a potential therapeutic target | PMID: 30594939 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 45.2 | High |
| Bone marrow | 32.1 | High |
| Lymph node | 28.7 | High |
| Spleen | 25.4 | High |
| Thymus | 22.0 | High |
| Colon | 8.5 | Medium |
| Breast | 6.2 | Medium |
| Lung | 4.8 | Low |
| Liver | 3.1 | Low |
| Brain | 1.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 38.5 | Cervical cancer cell line; high expression |
| MCF7 | 29.3 | Breast cancer cell line; high expression |
| A549 | 22.1 | Lung carcinoma cell line; moderate expression |
| HepG2 | 18.7 | Hepatocellular carcinoma; moderate expression |
| K562 | 15.2 | Leukemia cell line; moderate expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.832G>A (p.Glu278Lys) | Missense | <0.1% in COSMIC | Unknown functional impact; rare variant |
| c.1045C>T (p.Arg349Trp) | Missense | <0.1% in COSMIC | Potential loss of CDK1 binding |
| c.1234_1235insA (p.Thr412Asnfs*5) | Frameshift | <0.1% in COSMIC | Predicted loss of function; truncation |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations that truncate the cyclin box domain impair CDK1 binding and kinase activation, leading to G2/M arrest.
Gain of Function (GOF)
Missense mutations that enhance cyclin B2 stability or CDK1 affinity may promote unscheduled mitotic entry and genomic instability.
Dominant Negative (DN)
Mutations that produce a truncated cyclin B2 lacking the destruction box can inhibit normal cyclin B2 degradation, causing mitotic arrest.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Cell Cycle (KEGG hsa04110)
• G2/M DNA damage checkpoint (Reactome R-HSA-69481)
• Cyclin B2-mediated events (Reactome R-HSA-157858)
Protein Summary
Cyclin B2 is a 398-amino acid protein (UniProt O95067) with a molecular weight of approximately 45 kDa. It contains a cyclin N-terminal domain (residues 42–160) and a cyclin C-terminal domain (residues 161–280) that mediate CDK1 binding and activation. The protein also harbors a destruction box (RxxLxxxxN) near the N-terminus required for ubiquitin-mediated degradation at the end of mitosis. Cyclin B2 localizes to the Golgi apparatus and centrosomes, where it regulates Golgi fragmentation and mitotic spindle assembly. Its expression is tightly regulated at the transcriptional and post-translational levels.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CCNB2 Knockout HEK293 Cell Line | EDJ-KQ1532 | Human | 9133 | Details Get a Quote |
| CCNB2 Knockout A-549 Cell Line | EDJ-KQ21185 | Human | 9133 | Details Get a Quote |
| CCNB2 Knockout HeLa Cell Line | EDJ-KQ21187 | Human | 9133 | Details Get a Quote |
| CCNB2 Knockout HCT 116 Cell Line | EDJ-KQ19826 | Human | 9133 | Details Get a Quote |
